On September 5, 2023, Eric Schmidt, a member of the Board of Directors of Relmada Therapeutics, Inc. notified the Company that he would resign from the Board, effective immediately. Dr. Schmidt also serves as Chairman of the Audit Committee of the Board and as a member of the Corporate Governance and Nominating Committee of the Board. Dr. Schmidt?s resignation is not due to any disagreement with the Company, the Company?s management or the Board on any matter relating to the Company?s operations, policies or practices.

Dr. Schmidt informed the Company that he would leave the Company?s Board due to compliance requirements related to his new role as a sell-side equity analyst at a Wall Street investment banking firm. Dr. Schmidt, a Class I director, has been a Board member since 2019.